PHS Stock Overview
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Photocure ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr4.68 |
52 Week High | kr5.13 |
52 Week Low | kr3.61 |
Beta | 0.89 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -63.15% |
5 Year Change | n/a |
Change since IPO | -21.34% |
Recent News & Updates
Recent updates
Shareholder Returns
PHS | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -3.1% | -2.0% |
1Y | n/a | -31.9% | -0.3% |
Return vs Industry: Insufficient data to determine how PHS performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PHS performed against the German Market.
Price Volatility
PHS volatility | |
---|---|
PHS Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PHS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 88 | Dan Schneider | www.photocure.com |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix.
Photocure ASA Fundamentals Summary
PHS fundamental statistics | |
---|---|
Market cap | €126.52m |
Earnings (TTM) | €22.74k |
Revenue (TTM) | €42.64m |
5,563x
P/E Ratio3.0x
P/S RatioIs PHS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHS income statement (TTM) | |
---|---|
Revenue | kr500.66m |
Cost of Revenue | kr26.14m |
Gross Profit | kr474.52m |
Other Expenses | kr474.25m |
Earnings | kr267.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 0.0098 |
Gross Margin | 94.78% |
Net Profit Margin | 0.053% |
Debt/Equity Ratio | 0% |
How did PHS perform over the long term?
See historical performance and comparison